Evidence map›Paper›PMID 40303392›Full record

ArticleFrontiers in immunology2025

Optimisation of the cultured ELISpot/Fluorospot technique for the selective investigation of SARS-CoV-2 reactive central memory T cells.

Jack R Jerome, Kirsty L Wilson, Joshuah Fialho, Georgia Goodchild, Monica D Prakash, Charlie McLeod, Peter C Richmond, Vasso Apostolopoulos, Katie L Flanagan, Magdalena Plebanski

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jack R JeromeSchool of Health and Biomedical Science, Royal Melbourne Institute of Technology University, Melbourne, VIC, Australia.
Kirsty L WilsonSchool of Health and Biomedical Science, Royal Melbourne Institute of Technology University, Melbourne, VIC, Australia.
Joshuah FialhoSchool of Health and Biomedical Science, Royal Melbourne Institute of Technology University, Melbourne, VIC, Australia.
Georgia GoodchildSchool of Health and Biomedical Science, Royal Melbourne Institute of Technology University, Melbourne, VIC, Australia.
Monica D PrakashSchool of Health and Biomedical Science, Royal Melbourne Institute of Technology University, Melbourne, VIC, Australia.
Charlie McLeodWesfarmers Centre of Vaccines and Infectious Diseases, Kids Research Institute of Australia, Perth, WA, Australia.
Peter C RichmondWesfarmers Centre of Vaccines and Infectious Diseases, Kids Research Institute of Australia, Perth, WA, Australia.
Vasso ApostolopoulosSchool of Health and Biomedical Science, Royal Melbourne Institute of Technology University, Melbourne, VIC, Australia.
Katie L FlanaganSchool of Health and Biomedical Science, Royal Melbourne Institute of Technology University, Melbourne, VIC, Australia.
Magdalena PlebanskiSchool of Health and Biomedical Science, Royal Melbourne Institute of Technology University, Melbourne, VIC, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: This study presents an optimised cultured ELISpot protocol for detecting central memory T-cell interferon gamma (IFNγ) responses against SARS-CoV-2 peptides following an initial priming with either peptides, or whole spike protein. Methods: Key variations optimised include the culture length, timing of exogenous survival signals (IL-2), and endpoint analysis modality and cell density to enhance assay sensitivity without compromising specificity for central memory T-cell IFNγ recall responses to cognate antigen. Results: We noted a culture duration of 10 days, combined with a delayed IL-2 administration on day 5 to enhance assay sensitivity while maintaining response specificity towards cognate antigen when compared with shorter culture periods or earlier exogenous survival signal provision. With regards to lower-frequency T-cell interactions, as we observed with our donor SARS-CoV-2 epitope responses, our findings suggest Fluorospot to be preferable to the chromogenic ELISpot modality, and an immediate cell washing after culture collection to better facilitate cognate antigen responses. Fluorospot enabled a higher cell density while minimising the generation of visual artefacts, meanwhile immediate cell washing was critical for improving endpoint assay sensitivity. CCR7+ cell depletion was used to demonstrate our optimised protocol to selectively demonstrate central memory T-cell responses. Lastly, we provide evidence for the capacity of our assay to delineate individual responding peptides following peptide pool priming, and to explore cross-reactivity between viral variant peptides. Conclusion: This work advances the methodology for investigating T-cell immunity, particularly in the context of SARS-CoV-2, and emphasises the balance between enhancing specific cognate central memory responses while limiting non-specific activation.

Indexed as

COVID-19Enzyme-Linked Immunospot AssayMemory T CellsSARS-CoV-2Cells, CulturedEpitopes, T-LymphocyteHumansImmunologic MemoryInterferon-gammaInterleukin-2Spike Glycoprotein, CoronavirusEpitopes, T-LymphocyteInterferon-gammaInterleukin-2Spike Glycoprotein, Coronavirusspike protein, SARS-CoV-2central memory T-cell responsesCOVIDCOVID-19ELISpotFluorospotimmune responsesmethodSARS-CoV-2

Identifiers

PMID40303392
PMCPMC12037488

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.